Now focused on integrating Allergan generics, Teva eyes ‘much larger’ specialty buy in 2017

Carly Helfand SAN FRANCISCO–After watching months of pharma's M&A wave from the sidelines, Teva finally made a splash this summer with an agreement to pick up Allergan's ...

Teva scores European patent victory for long-acting Copaxone

Carly Helfand After fighting a long battle over the IP shield on lead drug Copaxone, Teva is feeling the heat from generics makers over the patent on its new, long-acting ...

Teva to divest $1B in assets to clear antitrust hurdles to Allergan deal: Reuters

Carly Helfand Back in July, Teva agreed to pick up Allergan's generics business for $ 40.5 billion. To get that deal past regulators, though, it's going to have to divest some ...

You want a formal offer, Mylan? Teva could have one this week

Carly Helfand Last month, Mylan Chairman Robert Coury challenged suitor Teva to either put up a formal bid or step aside and let his company proceed with its plan to pursue its own ...

Teva passed up an opportunity to buy Mylan target Perrigo: Globes

Carly Helfand So far, Perrigo hasn't seemed too keen on selling itself to generics giant Mylan. It's rejected the U.S. drugmaker three times. But word has it that Perrigo tried ...

‘No path forward’ with Teva, Mylan pledges amid warring roadshows

Carly Helfand Late last month, Teva kicked off a roadshow to meet shareholders of its buyout target, Mylan, and find out what price it'll need to put forth to convince them to support ...

One ‘cultural difference’ between Teva and Mylan? Coury’s $22.5M pay wouldn’t fly at Teva

Carly Helfand Since before Teva even made its now-rejected $ 40 billion offer to buy Mylan, its target's exec chairman, Robert Coury, has been pretty down on the idea, citing a ...

Teva ‘likely’ violated FCPA, local laws in Russia, Latin America and elsewhere

Carly Helfand Teva has been investigating for some time whether its business practices abroad have breached the Foreign Corrupt Practices Act (FCPA) and/or local laws. And now, it says ...

Cost-cutting, check. Now, it’s on to dealmaking, Teva chief says

Carly Helfand Teva is ready to make some deals now. It's a mantra that's seen quite a bit of play since CEO Erez Vigodman took up the reins at the generics giant early last ...

Copaxone, still growing, helps Teva pass Q3 estimates

Carly Helfand Sales of Teva's multiple sclerosis drug, Copaxone, are still growing–at least for now. The Israeli company's top-seller, whose patent is currently the subject ...

If Teva wanted a clear sign from Supreme Court on Copaxone, no such luck

Carly Helfand Teva's been waiting a long time to get its Copaxone patent appeal before the Supreme Court. And now that the court has heard oral arguments, it seems to be divided ...

Is Teva knocking on Mylan’s door? With inversion deal at risk, maybe

Carly Helfand Teva and Mylan merge? Rumors are certainly swirling–and not for the first time, either. But while a potential deal might make financial sense, at least one analyst ...
Page 1 of 512345
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS